在资源多样化的环境中对老年人重新考虑全球他类药物指南
Journal of global health
|December 4, 2025
概括
对于老年人来说,需要对低收入和中等收入国家 (LMICs) 进行调整. 情境敏感的方法对于公平的心血管疾病预防至关重要,考虑到当地医疗保健能力和生物变异.
科学领域:
- 预防心血管疾病 预防心血管疾病
- 全球卫生平等全球卫生平等
- 基于证据的医学 基于证据的医学
背景情况:
- 目前针对老年人的他类药物指南主要基于高收入国家 (HIC) 的数据,限制了其在低收入和中等收入国家 (LMIC) 的适用性.
- 在HIC指南 (例如,SCORE2,PREVENT) 和LMIC框架 (例如,WHO图表,HEARTS) 之间存在差异,影响临床建议.
- 挑战包括不同的医疗保健能力,多药商的担忧,潜在的不良影响和LMICs有限的监测.
研究的目的:
- 突出目前在LMICs的他类药物指南的局限性.
- 为老年人使用他类药物提出一个情境敏感的方法.
- 在全球范围内倡导公平和可行的心血管疾病预防战略.
主要方法:
- 在HIC和LMIC中审查现有的他类药物指南和实施框架.
- 对老年人胆固醇降低疗法的新兴生物证据的分析.
- 为情境敏感的药物决策制定指导原则的制定.
主要成果:
- 同样的患者可能会根据地理背景接受不同的他类药物建议.
- 现有的LMIC框架缺乏HIC指南的临床特异性.
- 新兴证据质疑所有老年人的统一类他类药物治疗.
结论:
- 药物指导方针必须适应区域能力,生物变异和实施现实.
- 必须采用情境敏感的方法,考虑功能状态和预后.
- 将他类药物的使用纳入初级保健,通过简化协议和任务共享,可以提高可行性和公平性.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Atherosclerosis III: Management
290
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
290
Drug Dosing: Geriatric Patients
199
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
199
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
200
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
200
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
176
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
176
Pharmacodynamics in Geriatric Patients: Effects of Age
172
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
172

